Evogliptin

Generic Name: Evogliptin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₆F_₃N_₃O_₃

CAS Number: 1222102-29-5

Unique Ingredient Identifier: 09118300L7

Background: Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

Phase 2

Active, not recruiting

Conditions: Calcific Aortic Valve Disease

Interventions: Drug: Placebo
Drug: Evogliptin

First Posted Date: 2021-12-03

Last Posted Date: 2024-12-18

Lead Sponsor: REDNVIA Co., Ltd.

Target Recruit Count: 867

Registration Number: NCT05143177

Locations: 🇺🇸
Mayo Clinic, AZ, Scottsdale, Arizona, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 24 locations

A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

Phase 4

Conditions: Bone Diseases, Metabolic
Diabetes Mellitus, Type 2

Interventions: Drug: Evogliptin
Drug: Dapagliflozin

First Posted Date: 2021-01-13

Last Posted Date: 2021-01-13

Lead Sponsor: Kyung Hee University Hospital at Gangdong

Target Recruit Count: 120

Registration Number: NCT04706637

Locations: 🇰🇷
The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
🇰🇷
Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of

and more 4 locations

Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

Phase 4

Not yet recruiting

Conditions: CAVD

Interventions: Drug: Evogliptin

First Posted Date: 2020-08-20

Last Posted Date: 2020-08-20

Lead Sponsor: Asan Medical Center

Target Recruit Count: 218

Registration Number: NCT04521452

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Evogliptin
Drug: Metformin and Evogliptin

First Posted Date: 2020-03-30

Last Posted Date: 2021-02-17

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 1971

Registration Number: NCT04326166

Locations: 🇰🇷
Sanggye paik pospital, Seoul, Nowon-gu, Korea, Republic of

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Phase 4

Completed

Conditions: Type2 Diabetes
Non-Alcoholic Fatty Liver Disease

Interventions: Drug: Evogliptin
Drug: Pioglitazone

First Posted Date: 2019-04-10

Last Posted Date: 2021-04-29

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 51

Registration Number: NCT03910361

Locations: 🇰🇷
Soonchunhyang University Hospital, Cheonan, Korea, Republic of
🇰🇷
Hanyang University Guri Hospital, Guri-si, Korea, Republic of
🇰🇷
Samsung Medical Center, Changwon, Korea, Republic of

and more 4 locations

Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency

Phase 2

Completed

Conditions: Type2 Diabetes Mellitus
Renal Insufficiency
Albuminuria

Interventions: Drug: Linagliptin
Drug: Evogliptin

First Posted Date: 2018-09-12

Last Posted Date: 2019-09-23

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 209

Registration Number: NCT03667300

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

Phase 4

Completed

Conditions: Type2 Diabetes

Interventions: Drug: Linagliptin
Drug: evogliptin

First Posted Date: 2016-11-28

Last Posted Date: 2018-07-23

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 207

Registration Number: NCT02974504

Locations: 🇰🇷
Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of

Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sitagliptin
Drug: evogliptin

First Posted Date: 2016-10-31

Last Posted Date: 2016-10-31

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 222

Registration Number: NCT02949193

Locations: 🇰🇷
Kangbuk Samsung Medical Center, Seoul, Korea, Republic of

Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

Phase 1

Completed

Conditions: Liver Dysfunction

Interventions: Drug: Evogliptin

First Posted Date: 2016-04-28

Last Posted Date: 2018-02-26

Lead Sponsor: Dong-A ST Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT02754219

Locations: 🇰🇷
Severance Hospital Clinical Trial Center, Seoul, Korea, Republic of

Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Evogliptin
Drug: Sitagliptin
Drug: Placebo Sitagliptin
Drug: Placebo Evogliptin

First Posted Date: 2016-02-23

Last Posted Date: 2018-08-14

Lead Sponsor: Eurofarma Laboratorios S.A.

Target Recruit Count: 146

Registration Number: NCT02689362

Locations: 🇧🇷
Clinica de Endocrinologia e Metabologia LTDA, São Paulo, Brazil
🇧🇷
CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda, Rio de Janeiro, Brazil
🇧🇷
CPCLIN - Centro de Pesquisas Clinicas LTDA, São Paulo, Brazil

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy